Viés de memória – foram utilizadas informações fornecidas pelos pacientes que podem, eventualmente, esquecer algum dado como, por exemplo, tempo de doença.
Viés de informação – foram utilizados dados de prontuários que podem estar incompletos ou incorretos.
Viés de seleção – os pacientes não foram randomizados, mas selecionados ao acaso, dentro de um serviço de referência.
6 CONSIDERAÇÕES FINAIS
A CR é uma importante complicação metabólica da AR que pode ter consequências negativas para os indivíduos acometidos como, por exemplo, o aumento do risco de desenvolvimento de doenças cardiovasculares. Apesar de ocorrer na maioria dos pacientes com AR, a CR ainda é negligenciada pelos reumatologistas.
Os grandes avanços que ocorreram no controle da inflamação sistêmica da AR nos últimos anos podem não ter o impacto esperado no aumento da sobrevida dos pacientes caso não sejam acompanhados de intervenções não farmacológicas como, por exemplo, a prática de atividade física, com destaque para os exercícios de fortalecimento muscular.
No presente estudo, houve uma redução da MM das pacientes com AR em comparação à MM das mulheres sem a doença. Entretanto, não houve associação entre a redução da MM na AR e marcadores de atividade e severidade da doença. Essa redução da MM de mulheres com AR encontrada no nosso estudo reforça a importância da avaliação da composição corporal nesse grupo de pacientes.
Devido à frequência relativamente elevada de CR encontrada no nosso estudo e devido ao fato de a excreção urinária de creatinina ser um exame sensível, de baixo custo e de fácil realização, os autores deste estudo sugerem que ele seja implantado na prática clínica do reumatologista para uma melhor avaliação dos pacientes com AR.
REFERENCIAS
1. Kvein TK, Scherer HU, Burmester, G-R. Rheumatoid Arthritis. In: Bijlsma JWJ, editor. EULAR Compendium on Rheumatic Diseases, 1st ed. Londres: BMJ Publishing Group Ltd, 2009. 61-80.
2. Summers GD, Metsios GS, Stavropoulos-Kalinoglou A, Kitas GD. Rheumatoid cachexia and cardiovascular disease. Nat Rev Rheumatol 2010 Aug;6(8):445-51.
3. Gonzalez A, Icen M, Kremers HM, Crowson CS, Davis JM, 3rd, Therneau TM, et al. Mortality trends in rheumatoid arthritis: the role of rheumatoid factor. J Rheumatol 2008 Jun;35(6):1009-14.
4. Farragher TM, Lunt M, Bunn DK, Silman AJ, Symmons DP. Early functional disability predicts both all-cause and cardiovascular mortality in people with inflammatory polyarthritis: results from the Norfolk Arthritis Register. Ann Rheum Dis 2007 Apr;66(4):486-92.
5. Naz SM, Symmons DP. Mortality in established rheumatoid arthritis. Best Pract Res Clin Rheumatol 2007 Oct;21(5):871-83.
6. Maradit-Kremers H, Nicola PJ, Crowson CS, Ballman KV, Gabriel SE. Cardiovascular death in rheumatoid arthritis: a population-based study. Arthritis Rheum 2005 Mar;52(3):722-32. 7. Symmons DP. Epidemiology of rheumatoid arthritis: determinants of onset, persistence and outcome. Best Pract Res Clin Rheumatol 2002 Dec;16(5):707-22.
8. Pincus T, Sokka T, Wolfe F. Premature mortality in patients with rheumatoid arthritis: evolving concepts. Arthritis Rheum [Editorial]. 2001 Jun;44(6):1234-6.
9. Wolfe F, Mitchell DM, Sibley JT, Fries JF, Bloch DA, Williams CA, et al. The mortality of rheumatoid arthritis. Arthritis Rheum 1994 Apr;37(4):481-94.
10. Rajbhandary R, Khezri A, Panush RS. Rheumatoid cachexia: what is it and why is it important? J Rheumatol [Editorial]. 2011 Mar;38(3):406-8.
11. Dao HH, Do QT, Sakamoto J. Abnormal body composition phenotypes in Vietnamese women with early rheumatoid arthritis. Rheumatology (Oxford) 2011 Jul;50(7):1250-8.
12. Giles JT, Allison M, Blumenthal RS, Post W, Gelber AC, Petri M, et al. Abdominal adiposity in rheumatoid arthritis: association with cardiometabolic risk factors and disease characteristics. Arthritis Rheum 2010 Nov;62(11):3173-82.
13. Metsios GS, Stavropoulos-Kalinoglou A, Panoulas VF, Sandoo A, Toms TE, Nevill AM, et al. Rheumatoid cachexia and cardiovascular disease. Clin Exp Rheumatol 2009 Nov- Dec;27(6):985-8.
14. Engvall IL, Elkan AC, Tengstrand B, Cederholm T, Brismar K, Hafstrom I. Cachexia in rheumatoid arthritis is associated with inflammatory activity, physical disability, and low bioavailable insulin-like growth factor. Scand J Rheumatol 2008 Sep-Oct;37(5):321-8.
15. Summers GD, Deighton CM, Rennie MJ, Booth AH. Rheumatoid cachexia: a clinical perspective. Rheumatology (Oxford) 2008 Aug;47(8):1124-31.
16. Giles JT, Ling SM, Ferrucci L, Bartlett SJ, Andersen RE, Towns M, et al. Abnormal body composition phenotypes in older rheumatoid arthritis patients: association with disease characteristics and pharmacotherapies. Arthritis Rheum 2008 Jun 15;59(6):807-15.
17. Giles JT, Bartlett SJ, Andersen RE, Fontaine KR, Bathon JM. Association of body composition with disability in rheumatoid arthritis: impact of appendicular fat and lean tissue mass. Arthritis Rheum 2008 Oct 15;59(10):1407-15.
18. Rall LC, Roubenoff R. Rheumatoid cachexia: metabolic abnormalities, mechanisms and interventions. Rheumatology (Oxford) 2004 Oct;43(10):1219-23.
19. Walsmith J, Roubenoff R. Cachexia in rheumatoid arthritis. Int J Cardiol 2002 Sep;85(1):89-99.
20. Ferraccioli G, Gremese E. Adiposity, joint and systemic inflammation: the additional risk of having a metabolic syndrome in rheumatoid arthritis. Swiss Med Wkly 2011;141:w13211. 21. Avina-Zubieta JA, Choi HK, Sadatsafavi M, Etminan M, Esdaile JM, Lacaille D. Risk of cardiovascular mortality in patients with rheumatoid arthritis: a meta-analysis of observational studies. Arthritis Rheum 2008 Dec 15;59(12):1690-7.
22. Goodson N, Marks J, Lunt M, Symmons D. Cardiovascular admissions and mortality in an inception cohort of patients with rheumatoid arthritis with onset in the 1980s and 1990s. Ann Rheum Dis 2005 Nov;64(11):1595-601.
23. Kitas GD, Erb N. Tackling ischaemic heart disease in rheumatoid arthritis. Rheumatology (Oxford) [Editorial]. 2003 May;42(5):607-13.
24. Solomon DH, Karlson EW, Rimm EB, Cannuscio CC, Mandl LA, Manson JE, et al. Cardiovascular morbidity and mortality in women diagnosed with rheumatoid arthritis. Circulation 2003 Mar 11;107(9):1303-7.
25. Douglas KM, Pace AV, Treharne GJ, Saratzis A, Nightingale P, Erb N, et al. Excess recurrent cardiac events in rheumatoid arthritis patients with acute coronary syndrome. Ann Rheum Dis 2006 Mar;65(3):348-53.
26. Roubenoff R, Roubenoff RA, Cannon JG, Kehayias JJ, Zhuang H, Dawson-Hughes B, et al. Rheumatoid cachexia: cytokine-driven hypermetabolism accompanying reduced body cell mass in chronic inflammation. J Clin Invest 1994 Jun;93(6):2379-86.
27. Binymin K, Herrick A, Carlson G, Hopkins S. The effect of disease activity on body composition and resting energy expenditure in patients with rheumatoid arthritis. J Inflamm Res 2011;4:61-6.
28. Chen YM, Chen HH, Hsieh CW, Hsieh TY, Lan JL, Chen DY. A close association of body cell mass loss with disease activity and disability in Chinese patients with rheumatoid arthritis. Clinics (Sao Paulo) 2011;66(7):1217-22.
29. Elkan AC, Hakansson N, Frostegard J, Cederholm T, Hafstrom I. Rheumatoid cachexia is associated with dyslipidemia and low levels of atheroprotective natural antibodies against phosphorylcholine but not with dietary fat in patients with rheumatoid arthritis: a cross-sectional study. Arthritis Res Ther 2009;11(2):R37.
30. Elkan AC, Engvall IL, Tengstrand B, Cederholm T, Hafstrom I. Malnutrition in women with rheumatoid arthritis is not revealed by clinical anthropometrical measurements or nutritional evaluation tools. Eur J Clin Nutr 2008 Oct;62(10):1239-47.
31. Hakkinen A, Pakarinen A, Hannonen P, Kautiainen H, Nyman K, Kraemer WJ, et al. Effects of prolonged combined strength and endurance training on physical fitness, body composition and serum hormones in women with rheumatoid arthritis and in healthy controls. Clin Exp Rheumatol 2005 Jul-Aug;23(4):505-12.
32. Roubenoff R, Walsmith J, Lundgren N, Snydman L, Dolnikowski GJ, Roberts S. Low physical activity reduces total energy expenditure in women with rheumatoid arthritis: implications for dietary intake recommendations. Am J Clin Nutr 2002 Oct;76(4):774-9.
33. Rall LC, Walsmith JM, Snydman L, Reichlin S, Veldhuis JD, Kehayias JJ, et al. Cachexia in rheumatoid arthritis is not explained by decreased growth hormone secretion. Arthritis Rheum 2002 Oct;46(10):2574-7.
34. Madsen OR, Egsmose C, Hansen B, Sorensen OH. Soft tissue composition, quadriceps strength, bone quality and bone mass in rheumatoid arthritis. Clin Exp Rheumatol 1998 Jan- Feb;16(1):27-32.
35. Elkan AC, Engvall IL, Cederholm T, Hafstrom I. Rheumatoid cachexia, central obesity and malnutrition in patients with low-active rheumatoid arthritis: feasibility of anthropometry, Mini Nutritional Assessment and body composition techniques. Eur J Nutr 2009 Aug;48(5):315- 22.
36. Morley JE, Thomas DR, Wilson MM. Cachexia: pathophysiology and clinical relevance. Am J Clin Nutr 2006 Apr;83(4):735-43.
37. Roubenoff R. Molecular basis of inflammation: relationships between catabolic cytokines, hormones, energy balance, and muscle. JPEN J Parenter Enteral Nutr 2008 Nov- Dec;32(6):630-2.
38. Metsios GS, Stavropoulos-Kalinoglou A, Douglas KM, Koutedakis Y, Nevill AM, Panoulas VF, et al. Blockade of tumour necrosis factor-alpha in rheumatoid arthritis: effects on components of rheumatoid cachexia. Rheumatology (Oxford) 2007 Dec;46(12):1824-7.
39. Stavropoulos-Kalinoglou A, Metsios GS, Koutedakis Y, Nevill AM, Douglas KM, Jamurtas A, et al. Redefining overweight and obesity in rheumatoid arthritis patients. Ann Rheum Dis 2007 Oct;66(10):1316-21.
40. Marcora S, Lemmey A, Maddison P. Dietary treatment of rheumatoid cachexia with beta- hydroxy-beta-methylbutyrate, glutamine and arginine: a randomised controlled trial. Clin Nutr 2005 Jun;24(3):442-54.
41. Marcora SM, Chester KR, Mittal G, Lemmey AB, Maddison PJ. Randomized phase 2 trial of anti-tumor necrosis factor therapy for cachexia in patients with early rheumatoid arthritis. Am J Clin Nutr 2006 Dec;84(6):1463-72.
42. Marcora SM, Lemmey AB, Maddison PJ. Can progressive resistance training reverse cachexia in patients with rheumatoid arthritis? Results of a pilot study. J Rheumatol 2005 Jun;32(6):1031-9.
43. Walsmith J, Abad L, Kehayias J, Roubenoff R. Tumor necrosis factor-alpha production is associated with less body cell mass in women with rheumatoid arthritis. J Rheumatol 2004 Jan;31(1):23-9.
44. Roubenoff R, Roubenoff RA, Ward LM, Holland SM, Hellmann DB. Rheumatoid cachexia: depletion of lean body mass in rheumatoid arthritis. Possible association with tumor necrosis factor. J Rheumatol 1992 Oct;19(10):1505-10.
45. Tilg H, Moschen AR. Adipocytokines: mediators linking adipose tissue, inflammation and immunity. Nat Rev Immunol 2006 Oct;6(10):772-83.
46. Choy EH, Panayi GS. Cytokine pathways and joint inflammation in rheumatoid arthritis. N Engl J Med [Review]. 2001 Mar 22;344(12):907-16.
47. Clowes GH, Jr., George BC, Villee CA, Jr., Saravis CA. Muscle proteolysis induced by a circulating peptide in patients with sepsis or trauma. N Engl J Med 1983 Mar 10;308(10):545-52. 48. Lecker SH, Solomon V, Mitch WE, Goldberg AL. Muscle protein breakdown and the critical role of the ubiquitin-proteasome pathway in normal and disease states. J Nutr 1999 Jan;129(1S Suppl):227S-37S.
49. Matschke V, Murphy P, Lemmey AB, Maddison PJ, Thom JM. Muscle quality, architecture, and activation in cachectic patients with rheumatoid arthritis. J Rheumatol 2010 Feb;37(2):282-4.
50. Metsios GS, Stavropoulos-Kalinoglou A, Panoulas VF, Koutedakis Y, Nevill AM, Douglas KM, et al. New resting energy expenditure prediction equations for patients with rheumatoid arthritis. Rheumatology (Oxford) 2008 Apr;47(4):500-6.
51. Arshad A, Rashid R, Benjamin K. The effect of disease activity on fat-free mass and resting energy expenditure in patients with rheumatoid arthritis versus noninflammatory arthropathies/soft tissue rheumatism. Mod Rheumatol 2007;17(6):470-5.
52. Mancuso CA, Rincon M, Sayles W, Paget SA. Comparison of energy expenditure from lifestyle physical activities between patients with rheumatoid arthritis and healthy controls. Arthritis Rheum 2007 May 15;57(4):672-8.
53. Cooney JK, Law RJ, Matschke V, Lemmey AB, Moore JP, Ahmad Y, et al. Benefits of exercise in rheumatoid arthritis. J Aging Res 2011;2011:681640.
54. Serelis J, Kontogianni MD, Katsiougiannis S, Bletsa M, Tektonidou MG, Skopouli FN. Effect of anti-TNF treatment on body composition and serum adiponectin levels of women with rheumatoid arthritis. Clin Rheumatol 2008 Jun;27(6):795-7.
55. Sarzi-Puttini P, Atzeni F, Scholmerich J, Cutolo M, Straub RH. Anti-TNF antibody treatment improves glucocorticoid induced insulin-like growth factor 1 (IGF1) resistance without influencing myoglobin and IGF1 binding proteins 1 and 3. Ann Rheum Dis 2006 Mar;65(3):301- 5.
56. Inaba M, Tanaka K, Goto H, Sakai S, Yamada S, Naka H, et al. Independent association of increased trunk fat with increased arterial stiffening in postmenopausal patients with rheumatoid arthritis. J Rheumatol 2007 Feb;34(2):290-5.
57. Dessein PH, Joffe BI, Stanwix AE. Inflammation, insulin resistance, and aberrant lipid metabolism as cardiovascular risk factors in rheumatoid arthritis. J Rheumatol [Editorial]. 2003 Jul;30(7):1403-5.
58. Dessein PH, Joffe BI, Stanwix A, Botha AS, Moomal Z. The acute phase response does not fully predict the presence of insulin resistance and dyslipidemia in inflammatory arthritis. J Rheumatol. 2002 Mar;29(3):462-6.
59. Kotler DP. Cachexia. Ann Intern Med 2000 Oct 17;133(8):622-34.
60. Westhovens R, Nijs J, Taelman V, Dequeker J. Body composition in rheumatoid arthritis. Br J Rheumatol 1997 Apr;36(4):444-8.
61. de Alvaro C, Teruel T, Hernandez R, Lorenzo M. Tumor necrosis factor alpha produces insulin resistance in skeletal muscle by activation of inhibitor kappaB kinase in a p38 MAPK- dependent manner. J Biol Chem 2004 Apr 23;279(17):17070-8.
62. Yamaguchi K, Higashiura K, Ura N, Murakami H, Hyakukoku M, Furuhashi M, et al. The effect of tumor necrosis factor-alpha on tissue specificity and selectivity to insulin signaling. Hypertens Res. 2003 May;26(5):389-96.
63. Book C, Karlsson MK, Akesson K, Jacobsson LT. Early rheumatoid arthritis and body composition. Rheumatology (Oxford) 2009 Sep;48(9):1128-32.
64. Elkan AC, Hakansson N, Frostegard J, Hafstrom I. Low level of physical activity in women with rheumatoid arthritis is associated with cardiovascular risk factors but not with body fat mass--a cross sectional study. BMC Musculoskelet Disord 2011;12:13.
65. Metsios GS, Stavropoulos-Kalinoglou A, Panoulas VF, Wilson M, Nevill AM, Koutedakis Y, et al. Association of physical inactivity with increased cardiovascular risk in patients with rheumatoid arthritis. Eur J Cardiovasc Prev Rehabil 2009 Apr;16(2):188-94.
66. Sahin G, Guler H, Incel N, Sezgin M, As I. Soft tissue composition, axial bone mineral density, and grip strength in postmenopausal Turkish women with early rheumatoid arthritis: Is
lean body mass a predictor of bone mineral density in rheumatoid arthritis? Int J Fertil Womens Med 2006 Mar-Apr;51(2):70-4.
67. Toussirot E, Nguyen NU, Dumoulin G, Aubin F, Cedoz JP, Wendling D. Relationship between growth hormone-IGF-I-IGFBP-3 axis and serum leptin levels with bone mass and body composition in patients with rheumatoid arthritis. Rheumatology (Oxford) 2005 Jan;44(1):120-5. 68. Westhoff G, Rau R, Zink A. Radiographic joint damage in early rheumatoid arthritis is highly dependent on body mass index. Arthritis Rheum 2007 Nov;56(11):3575-82.
69. Escalante A, Haas RW, del Rincon I. Paradoxical effect of body mass index on survival in rheumatoid arthritis: role of comorbidity and systemic inflammation. Arch Intern Med 2005 Jul 25;165(14):1624-9.
70. Kremers HM, Nicola PJ, Crowson CS, Ballman KV, Gabriel SE. Prognostic importance of low body mass index in relation to cardiovascular mortality in rheumatoid arthritis. Arthritis Rheum 2004 Nov;50(11):3450-7.
71. Roubenoff R, Freeman LM, Smith DE, Abad LW, Dinarello CA, Kehayias JJ. Adjuvant arthritis as a model of inflammatory cachexia. Arthritis Rheum 1997 Mar;40(3):534-9.
72. Lang T, Streeper T, Cawthon P, Baldwin K, Taaffe DR, Harris TB. Sarcopenia: etiology, clinical consequences, intervention, and assessment. Osteoporos Int 2010 Apr;21(4):543-59. 73. von Haehling S, Morley JE, Anker SD. An overview of sarcopenia: facts and numbers on prevalence and clinical impact. J Cachexia Sarcopenia Muscle 2010 Dec;1(2):129-33.
74. Lee SJ, Janssen I, Heymsfield SB, Ross R. Relation between whole-body and regional measures of human skeletal muscle. Am J Clin Nutr 2004 Nov;80(5):1215-21.
75. Wang Z, St-Onge MP, Lecumberri B, Pi-Sunyer FX, Heshka S, Wang J, et al. Body cell mass: model development and validation at the cellular level of body composition. Am J Physiol Endocrinol Metab 2004 Jan;286(1):E123-8.
76. Lee RC, Wang ZM, Heymsfield SB. Skeletal muscle mass and aging: regional and whole-body measurement methods. Can J Appl Physiol 2001 Feb;26(1):102-22.
77. Kyle UG, Genton L, Hans D, Karsegard L, Slosman DO, Pichard C. Age-related differences in fat-free mass, skeletal muscle, body cell mass and fat mass between 18 and 94 years. Eur J Clin Nutr 2001 Aug;55(8):663-72.
78. Ellis KJ. Human body composition: in vivo methods. Physiol Rev 2000 Apr;80(2):649- 80.
79. Mitsiopoulos N, Baumgartner RN, Heymsfield SB, Lyons W, Gallagher D, Ross R. Cadaver validation of skeletal muscle measurement by magnetic resonance imaging and computerized tomography. J Appl Physiol 1998 Jul;85(1):115-22.
80. Helliwell PS, Jackson S. Relationship between weakness and muscle wasting in rheumatoid arthritis. Ann Rheum Dis 1994 Nov;53(11):726-8.
81. Roubenoff R, Roubenoff RA, Ward LM, Stevens MB. Catabolic effects of high-dose corticosteroids persist despite therapeutic benefit in rheumatoid arthritis. Am J Clin Nutr 1990 Dec;52(6):1113-7.
82. Proctor DN, O'Brien PC, Atkinson EJ, Nair KS. Comparison of techniques to estimate total body skeletal muscle mass in people of different age groups. Am J Physiol 1999 Sep;277(3 Pt 1):E489-95.
83. Lee RC, Wang Z, Heo M, Ross R, Janssen I, Heymsfield SB. Total-body skeletal muscle mass: development and cross-validation of anthropometric prediction models. Am J Clin Nutr 2000 Sep;72(3):796-803.
84. Salamone LM, Fuerst T, Visser M, Kern M, Lang T, Dockrell M, et al. Measurement of fat mass using DEXA: a validation study in elderly adults. J Appl Physiol 2000 Jul;89(1):345-52. 85. Book C, Karlsson MK, Nilsson JA, Akesson K, Jacobsson LT. Changes in body composition after 2 years with rheumatoid arthritis. Scand J Rheumatol 2011 Mar;40(2):95-100. 86. Munro R, Capell H. Prevalence of low body mass in rheumatoid arthritis: association with the acute phase response. Ann Rheum Dis 1997 May;56(5):326-9.
87. Engelhart M, Kondrup J, Hoie LH, Andersen V, Kristensen JH, Heitmann BL. Weight reduction in obese patients with rheumatoid arthritis, with preservation of body cell mass and improvement of physical fitness. Clin Exp Rheumatol 1996 May-Jun;14(3):289-93.
88. Hernandez-Beriain JA, Segura-Garcia C, Rodriguez-Lozano B, Bustabad S, Gantes M, Gonzalez T. Undernutrition in rheumatoid arthritis patients with disability. Scand J Rheumatol 1996;25(6):383-7.
89. Sambrook PN, Spector TD, Seeman E, Bellamy N, Buchanan RR, Duffy DL, et al. Osteoporosis in rheumatoid arthritis. A monozygotic co-twin control study. Arthritis Rheum 1995 Jun;38(6):806-9.
90. Kalla AA, Brown GM, Meyers OL. Nutritional status in rheumatoid arthritis. Effects of disease activity, corticosteroid therapy and functional impairment. S Afr Med J 1992 Dec;82(6):411-4.
91. Roubenoff R, Kehayias JJ. The meaning and measurement of lean body mass. Nutr Rev 1991 Jun;49(6):163-75.
92. Kotler DP, Tierney AR, Wang J, Pierson RN, Jr. Magnitude of body-cell-mass depletion and the timing of death from wasting in AIDS. Am J Clin Nutr 1989 Sep;50(3):444-7.
93. Kalantar-Zadeh K. What is so bad about reverse epidemiology anyway? Semin Dial 2007 Nov-Dec;20(6):593-601.
94. Armstrong DJ, McCausland EM, Quinn AD, Wright GD. Obesity and cardiovascular risk factors in rheumatoid arthritis. Rheumatology (Oxford) 2006 Jun;45(6):782; author reply -3. 95. Dagenais GR, Yi Q, Mann JF, Bosch J, Pogue J, Yusuf S. Prognostic impact of body weight and abdominal obesity in women and men with cardiovascular disease. Am Heart J 2005 Jan;149(1):54-60.
96. Shibuya K, Hagino H, Morio Y, Teshima R. Cross-sectional and longitudinal study of osteoporosis in patients with rheumatoid arthritis. Clin Rheumatol 2002 May;21(2):150-8.
97. Lemmey AB, Williams SL, Marcora SM, Jones J, Maddison PJ. Are the benefits of a high-intensity progressive resistance training program sustained in rheumatoid arthritis patients? A 3-year followup study. Arthritis Care Res (Hoboken) 2012 Jan;64(1):71-5.
98. Baillet A, Vaillant M, Guinot M, Juvin R, Gaudin P. Efficacy of resistance exercises in rheumatoid arthritis: meta-analysis of randomized controlled trials. Rheumatology (Oxford) 2012 Mar;51(3):519-27.
99. Strasser B, Leeb G, Strehblow C, Schobersberger W, Haber P, Cauza E. The effects of strength and endurance training in patients with rheumatoid arthritis. Clin Rheumatol 2011 May;30(5):623-32.
100. Lemmey AB, Marcora SM, Chester K, Wilson S, Casanova F, Maddison PJ. Effects of high-intensity resistance training in patients with rheumatoid arthritis: a randomized controlled trial. Arthritis Rheum 2009 Dec 15;61(12):1726-34.
101. Akner G, Cederholm T. Treatment of protein-energy malnutrition in chronic nonmalignant disorders. Am J Clin Nutr 2001 Jul;74(1):6-24.
102. Rall LC, Meydani SN, Kehayias JJ, Dawson-Hughes B, Roubenoff R. The effect of progressive resistance training in rheumatoid arthritis. Increased strength without changes in energy balance or body composition. Arthritis Rheum 1996 Mar;39(3):415-26.
103. Hakkinen A, Hakkinen K, Hannonen P. Effects of strength training on neuromuscular function and disease activity in patients with recent-onset inflammatory arthritis. Scand J Rheumatol 1994;23(5):237-42.
104. de Jong Z, Munneke M, Jansen LM, Ronday K, van Schaardenburg DJ, Brand R, et al. Differences between participants and nonparticipants in an exercise trial for adults with rheumatoid arthritis. Arthritis Rheum 2004 Aug 15;51(4):593-600.
105. Hakkinen A, Sokka T, Kotaniemi A, Kautiainen H, Jappinen I, Laitinen L, et al. Dynamic strength training in patients with early rheumatoid arthritis increases muscle strength but not bone mineral density. J Rheumatol 1999 Jun;26(6):1257-63.
106. Neuberger GB, Aaronson LS, Gajewski B, Embretson SE, Cagle PE, Loudon JK, et al. Predictors of exercise and effects of exercise on symptoms, function, aerobic fitness, and disease outcomes of rheumatoid arthritis. Arthritis Rheum 2007 Aug 15;57(6):943-52.
107. Stenstrom CH, Minor MA. Evidence for the benefit of aerobic and strengthening exercise in rheumatoid arthritis. Arthritis Rheum 2003 Jun 15;49(3):428-34.
108. Scott DL, Kingsley GH. Tumor necrosis factor inhibitors for rheumatoid arthritis. N Engl J Med 2006 Aug 17;355(7):704-12.
109. Engvall IL, Tengstrand B, Brismar K, Hafstrom I. Infliximab therapy increases body fat mass in early rheumatoid arthritis independently of changes in disease activity and levels of leptin and adiponectin: a randomised study over 21 months. Arthritis Res Ther 2010;12(5):R197. 110. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988 Mar;31(3):315-24.
111. Bruce B, Fries JF. The Stanford Health Assessment Questionnaire: dimensions and practical applications. Health Qual Life Outcomes. 2003;1:20.
112. Fries JF, Spitz P, Kraines RG, Holman HR. Measurement of patient outcome in arthritis. Arthritis Rheum 1980 Feb;23(2):137-45.
113. Aletaha D, Smolen J. The Simplified Disease Activity Index (SDAI) and the Clinical Disease Activity Index (CDAI): a review of their usefulness and validity in rheumatoid arthritis. Clin Exp Rheumatol 2005 Sep-Oct;23(5 Suppl 39):S100-8.
114. Gallagher D, Visser M, Sepulveda D, Pierson RN, Harris T, Heymsfield SB. How useful is body mass index for comparison of body fatness across age, sex, and ethnic groups? Am J Epidemiol 1996 Feb 1;143(3):228-39.
115. Janssen I, Baumgartner RN, Ross R, Rosenberg IH, Roubenoff R. Skeletal muscle cutpoints associated with elevated physical disability risk in older men and women. Am J Epidemiol 2004 Feb 15;159(4):413-21.
116. Altman, DG. Practical Statistics for Medical Research. Chapman and Hall London: Chapman and Hall 1991.